Why is "Bacillus Calmette-Guérin" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-06-03 02:34:10
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Bacillus_Calmette-Guérin entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-06-03 and was most recently seen on 2026-06-03.
Wikipedia Overview
The Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). It is named after its inventors Albert Calmette and Camille Guérin. In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as soon after birth as possible. In areas where tuberculosis is not common, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested for and treated. Adults who are frequently exposed to tuberculosis may also be immunized. BCG has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacterial infections. It is also often used as part of the treatment of bladder cancer.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Bacillus Calmette–Guérin (BCG) immunotherapy reprograms CNS immunity and alters Alzheimer’s biomarkers: results from two open-label clinical trials - Nature
-
Beyond the bladder: case series of Mycobacterium bovis bacillus Calmette-Guérin infections following intravesical instillation - ASM Journals
-
Pain Response and Associated Factors During Bacillus Calmette-Guérin Vaccination in Newborns: A Cross-Sectional Study - Cureus
-
Bacillus Calmette-Guérin immunotherapy-induced extracellular vesicles promote antitumor immunity in bladder cancer - Frontiers
-
Recent Developments in Bacillus Calmette-Guérin-Unresponsive Non-muscle Invasive Bladder Cancer Research: The SunRISe 1 Study – Clinical Opinion - EMJ
-
Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer. - AstraZeneca
-
FDA Approves Durvalumab and BCG for High-Risk NMIBC - Oncology Nursing News
-
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC - The ASCO Post
-
Bacillus Calmette-Guérin (BCG) vaccination: a global analysis of cost-effectiveness and optimal safety stock - medRxiv
-
Alzheimer's Biomarkers Change After Tuberculosis Vaccination - medpagetoday.com
-
Recombinant BCG Plus Chemoimmunotherapy May Up Anticancer Effect in MIBC - Renal and Urology News
-
Detalimogene Therapy Tied to Responses in Heavily Pretreated, BCG-unresponsive NMIBC - Oncology News Central
-
A machine-learning approach to predict additional treatment after Bacillus Calmette-Guérin induction in non-muscle-invasive bladder cancer - Nature
-
Bacillus Calmette-Guérin (BCG)-Associated Secondary Hemophagocytic Lymphohistiocytosis Mimicking Sepsis and Multiorgan Dysfunction: A Case Report - Cureus
-
Durvalumab Plus BCG Shows Promise for High-Risk NMIBC - Oncology News Central
-
BCG after trimodality therapy: managing non-muscle-invasive recurrence in the irradiated bladder - Frontiers
-
Tuberculous Miliary Disease Following Intravesical Bacillus Calmette-Guérin Therapy for Urothelial Carcinoma of the Bladder: A Case Report - Cureus
-
Breed-specific innate immune responses to Brucella abortus strain RB51 and Bacillus Calmette-Guérin in cattle - Nature
-
Chronic Granulomatous Interstitial Nephritis Presenting Five Years After Intravesical Bacillus Calmette-Guérin Therapy: A Case Report and Literature Review - Cureus
-
Understanding Treatment Completion and Tolerability of Intravesical Bacillus Calmette-Guérin (BCG) for Non-muscle Invasive Bladder Cancer in a Single UK Health Board - Cureus
-
BCG vaccine may remodel the human brain's immune environment - News-Medical
-
Tuberculosis Vaccine Reprograms Brain Immunity in Small Trial - the-scientist.com
-
FDA approves durvalumab plus BCG for BCG-naïve, high-risk NMIBC - Urology Times
-
Mark Tyson, MD, highlights additional safety data on durvalumab plus BCG in BCG-naive NMIBC - Urology Times
-
A century-old vaccine may have an unexpected role in protecting the brain - Gavi, the Vaccine Alliance
-
Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer - The ASCO Post
-
Nogapendekin Alfa Plus BCG Exhibits Efficacy Advantage in NMIBC in Situ - CancerNetwork
-
Durvalumab plus BCG shows consistent DFS benefit in older patients with high-risk NMIBC - Urology Times
-
EAU 2026: Case-Based Panel Discussion High-Risk NMIBC Post-BCG Failure: Spare the Bladder? Bladder Sparing: Trial Overview, Other Intravesical Options - UroToday
-
Supplemental BLA for Nogapendekin in Bladder Cancer Resubmitted to FDA - Targeted Oncology
-
Advances in bladder-preserving treatment for BCG-unresponsive non-muscle invasive bladder cancer - Mayo Clinic
-
EAU 2026: BCG + Mitomycin Versus BCG Alone as Adjuvant Intravesical Therapy for High-Risk NMIBC: Effects on Urinary Symptoms and Other Aspects of Health Related Quality of Life in a Randomized Trial (ANZUP 1301) - UroToday
-
Kristen Scarpato, MD, on combination strategies in BCG-naïve NMIBC - Urology Times
-
Key Findings from the CREST Trial and Implications for BCG-Naïve NMIBC - Urology Times
-
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 - BioSpace
-
Bradley McGregor, MD, discusses BCG–immunotherapy data in high-risk NMIBC - Urology Times
-
Prediction of recurrence using hematologic and urinary markers in intravesical Bacillus calmette Guerin treated bladder cancer - Nature
-
Tuberculosis Vaccine May Help Prevent Alzheimer's by Influencing the Brain's Immune System - Discover Magazine
-
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS - BioSpace
-
Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice - Nature
-
WHO technical briefing: novel tuberculosis vaccines and the Global Tuberculosis Vaccine Accelerator Council for countries of Eastern Europe and Central Asia - who.int
-
FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer - medpagetoday.com
-
FDA receives resubmitted sBLA for NAI plus BCG in papillary NMIBC - Urology Times
-
Immunotherapy for High-Risk Non–Muscle-Invasive Bladder Cancer: Is BCG Enough? - ASCO Daily News
-
Case report: IL12RB1 deficiency in an infant with disseminated Bacille Calmette-Guérin disease - Frontiers
-
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer - The ASCO Post
-
Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer - The ASCO Post
-
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 - Business Wire
-
Low-density lipoprotein cholesterol drives multinucleated giant cell formation in response to mycobacterium bovis Bacille Calmette-Guérin - Nature
-
Addressing Unmet Needs and Navigating BCG Shortages in High-Risk NMIBC - Urology Times
-
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors - BioSpace
-
Atezolizumab Fails to Enhance BCG in Non–Muscle-Invasive Bladder Cancer - Targeted Oncology
-
Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA - Business Wire
-
ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe - ImmunityBio
-
BCG and Beyond: Is Systemic Immunotherapy Progress or Overreach in BCG-Naïve NMIBC? - Oncodaily
-
ImmunityBio has signed an exclusive US agreement with the Japanese BCG Laboratory to introduce the Tokyo strain BCG (Bacillus Calmette-Guérin vaccine). - Bitget
-
Impact of intravesical BCG Therapy on quality of life in non–muscle-invasive bladder cancer: a prospective evaluation using the FACT-Bl questionnaire - www.elsevier.com
-
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries - Business Wire
-
Remodelling of immune system by TB vaccine may explain its link with lower Alzheimer's risk: Study - ET HealthWorld
-
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19 - Nature
-
Psoriatic Skin Lesions Induced by the Bacillus Calmette-Guerin (BCG) Vaccination in a Child With Latent Tuberculosis Infection: A Case Report - Cureus
-
The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin vaccine - Nature
-
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer - Business Wire
-
Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer - www.elsevier.com
-
Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity - Wiley Online Library
-
The impact of interferon-γ pathway on trained immunity induction by vaccination with Bacille Calmette-Guérin - Nature
-
TAR-200 Leads to Durable Responses in Bacillus Calmette–Guérin-Unresponsive NMIBC - OncLive
-
BCG shortage for intravesical instillation is associated with early tumoral recurrence in patients with high-risk non-muscle invasive bladder tumours - www.elsevier.com
-
Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer - The Lancet
-
Mycobacterium bovis Bacillus Calmette-Guérin (BCG)-Related Sternal Osteomyelitis - Cureus
-
Systemic Bacillus Calmette-Guérin (BCG) Infection With Renal Involvement: A Rare Complication of BCG Immunotherapy - Cureus
-
Exploring Nonsurgical Salvage Options for Bacillus Calmette-Guérin–Unresponsive Carcinoma In Situ of the Bladder: An Evolving Algorithm - ASCO Daily News
-
Is a reduced bacillus Calmette-Guérin regimen feasible? - Urology Times
-
Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy - www.elsevier.com
-
Clinical & Translational Immunology | ASI Journal - Wiley Online Library
-
Unraveling Bacillus Calmette-Guérin (BCG) Therapy Side Effects in Bladder Cancer: A Tale of Triumph Over Treatment Challenges - Cureus
-
Systemic Bacillus Calmette-Guérin (BCG) Infection in a Patient With Non-Muscle-Invasive Bladder Cancer: A Case Report - Cureus
-
First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer - Cure Today
-
Systemic Bacillus Calmette-Guerin Infection One Year After Intravesical Immunotherapy Mimicking Sarcoidosis - Cureus
-
Refractory Hypercalcemia in Nongranulomatous Disseminated Bacillus Calmette-Guérin Infection - Consultant360
-
The bacillus Calmette–Guérin vaccination allows the innate immune system to provide protection from severe COVID-19 infection - PNAS
-
FDA Approves J&J’s Inlexzo for Bacillus Calmette-Guérin-Unresponsive, Non-Muscle Invasive Bladder Cancer - Pharmaceutical Executive
-
Bladder Cancer Progression Despite BCG Therapy Predicts Worse Outcomes - Renal and Urology News
-
Epidemiology of childhood tuberculosis after ceasing universal Bacillus Calmette–Guérin vaccination - Nature
-
The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article - Cureus
-
Comparison of Intravesical Bacillus Calmette-Guérin (BCG) and Mitomycin C for the Treatment of Non-Muscle-Invasive Bladder Cancer - Cureus
-
Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer - The Lancet
-
FDA Approves Anktiva Plus Bacillus Calmette-Guérin For Non-Muscle Invasive Bladder Cancer - Pharmacy Times
-
Storable Polydopamine Nanoparticles Combined with Bacillus Calmette-Guérin for Photothermal-Immunotherapy of Colorectal Cancer - John Wiley
-
BCANTT 2025: The PRIME (S1602) Trial: Effectiveness of Different Bacillus Calmette-Guérin (BCG) Regimens in Patients with CIS, High-Grade Ta, or High-Grade T1 Non–muscle-Invasive Bladder Cancer (NMIBC) - UroToday
-
Analysis of risk factors for post-bacillus Calmette–Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer - Nature
-
Dr. Fairlie and the Breakthrough in the Fight Against TB - The Borgen Project
-
Distinct gene expression signatures comparing latent tuberculosis infection with different routes of Bacillus Calmette-Guérin vaccination - Nature
-
ASCO GU 2025: Case-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-Guérin - UroToday
-
Disseminated BCGosis After Intravesical BCG Installation for Bladder Cancer - Wiley Online Library
-
Heightened IDO1 levels predict Bacillus Calmette-Guèrin failure in high-risk non-muscle-invasive bladder cancer patients - Nature
-
Conundrums in Bacillus Calmette Guerin (BCG) Unresponsive Nonmuscle Invasive Bladder Cancer Trials - Roger Li - UroToday
-
BCG Vaccine Shows Early Potential to Influence Alzheimer's-Related Immune Markers: Study - Medical Dialogues
-
Bacillus Calmette-Guérin (BCG)-Induced Pneumonitis: A Case Report - Cureus
-
Safety and Tolerability of TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer in SUNRISE-1 - Siamak Daneshmand - UroToday
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.